


Innovazione e sviluppo del prodotto Il settore farmaceutico (1)

Paolo Barbanti Ph.D., MBA

pbarbanti@liuc.it

Paolo Barbanti Innovazione e sviluppo del prodotto

Delivering transformative innovation




Advancing research and development of new therapies in many disease areas

Building new technology platforms

- cell and gene therapies
- radioligand therapies

Integrating data science and digital technologies into research and development

Pioneering breakthrough approaches in multiple disease areas





Curing cancer



Treating asthma



Eliminating malaria



Access to biologics



Fighting liver disease



Conquering heart failure




Restoring sight

aolo Barbanti

A golden age for medical science





Source: US FDA website "Drugs/NDA and BLA Calendar Year Approvals" <u>https://www.fda.gov/drugs/nda-and-bla-approvals/nda-and-bla-calendar-year-approvals</u>



Demographic trends are changing healthcare



Growing populations

+1bn_{by}2030

About 8.5 billion people are expected to inhabit the planet by the year 2030

Source: UN "World Population Prospects 2019" brochure https://population.un.org/wpp/Publications/Files/WPP2019_Highlights.pdf



Demographic trends are changing healthcare



Rapid aging


+500mn_{over} 60 by 2030

About 1.4 billion people worldwide are projected to be 60 or older by the year 2030, fueling a rise in chronic illness

Source: UN "World Population Prospects 2019" brochure https://population.un.org/wpp/Publications/Files/WPP2019 Highlights.pdf



Working to deliver better health outcomes for patients



Outcome-based pricing Real-world evidence of effectiveness **Data and analytics Digital health, "beyond** the pill" Health system capacity building



We need to Reimagine Medicine



How we fight disease




How we deliver treatments



How we operate




The path to a new medicine



Paolo Barbanti Management Consulting Pharma & Bistopch

On the forefront of the next generation of drug discovery



Innovate the new science of therapeutics

Promote connectedness to innovators beyond our walls

Tap digital technologies to transform drug discovery



Digital Transformation

Digital Transformation In The Music Business:



Alvaro Rebollo Ena Follow Mar 24 · 7 min read

What Other Businesses Could Have Learnt From It, And The Convergence (or Not) of Spotify and Netflix



I stepped in the music business in the year 2000. I was really lucky to be able to experience the final days of the majors' golden age: A lot of CDs were sold, massive media campaigns were launched, piracy on the Internet was still inexistent, revenues were not that bad...



Digital Transformation... It is its turn

duval union consulting



1995+

USIC PHOTOGRAPHY VIDEO RENTAL

2005+

PRINT MEDIA TV TRAVEL HR

2015+

RETAIL AUTOMOTIVE TRAVEL EDUCATION TELCO FOOD/FMCG BANKING/INSURANCE NEALTHCARE

2025

ALL SAFE HAVENS WILL BE SUBJECT TO DIGITAL DISRUPTION

<u>It is 2025...</u>





Digital Therapeutics: pharma's threat or opportunity





Paul Simms Chairman eyeforpharma



Jim O'Donoghue President S3 Connected Health

Welcome

It is 2025 and digitally delivered therapies are now part of our regular healthcare experience. The smartphone, already our first port of call on health matters, has been elevated to the role of personal health mentor and condition management guide.

Offering us therapies and advice, both consciously and subconsciously, our device acts as our general healthcare concierge too, knowing when we've taken our medicine, showing us ways to optimize our desired lifestyle and determining medication dosages, and inviting us to visit specialists when they detect anomalous data. We are even seeing the emergence of the digital twin, a virtual version of yourself which can 'trial' treatments on your behalf before being adopted in your real body.

And clinicians, in a different role from the past, now rely on the data from your device too. They sanction or suggest technology-enabled patient services offering treatments that in many cases do not involve a chemical or biological intervention, but a digital one.

These therapies now routinely generate data in real time for deeplearning AI to interpret, enabling care providers to automate routine aspects of care, for example through alerts and 'bot' consultations, which give patients much of the information they need to stay compliant with their care plans.

Digital technologies act as a force multiplier for clinicians at all levels from consultants to nurses, who are now able to focus their time on the patients in most need and with the most complex ailments. Where necessary, the AI alerts a clinician to the need to intervene and assists them in making rapid decisions on the best and most appropriate course of action.

Meanwhile, payers rely on the rich real-world dataset that is now generated from these technologies and are used as an integral part of outcome based contracting without adding excessive burden to health systems. Digital therapeutics (DTx) are now a core part of the payer's arsenal of care delivery tools, having in many cases proven their worth in driving better care alongside analog medicines or, where they replace chemical alternatives, they do so often at a far lower cost. DTx revenues have ballooned as payers and HTAs see the value of recommending and prescribing them outright.


And in general, we now have a more proactive, voluntary health system where citizens actively prevent rather than simply manage their exposure to chronic diseases, moving the dial on population health at a global level whilst driving down costs. Healthcare systems under ever-increasing pressure from ageing populations can now do more with less. Patients are enjoying more quality years of wellness than they would have expected a decade before.

Digital Transformation in Healthcare

Perspective

Page 1 of 8


Digital health is a cultural transformation of traditional healthcare



Traditional healthcare



The Journey to 2025 – Driving Forces



The biggest challenge to health and healthcare

<u>Chronic</u>

Leading causes of disability, 1990 and 2017

Global all-age YLDs

1990 rank

1 Low back pain

2 Headache disorders**

3 Dietary iron deficiency

4 Depressive disorders

5 COPD

6 Age-related hearing loss

9 Diabetes

Communicable, maternal, neonatal, and nutritional diseases Non-communicable diseases

2017 rank 1 Low back pain 2 Headache disorders** 3 Depressive disorders 4 Diabetes 5 Age-related hearing loss 6 COPD[†]

7 Dietary iron deficiency

"Headache disorders mainly include migraine.

[†]Chronic obstructive pulmonary disease

Drugs are not

enough!

- Support
- Education
- Monitoring
- Adherence

we need something

more...



Paolo Barbanti

Patients - What do they want?

- Take control of their health
- Empowerement
- De-centralization
- Home Testing for Chronic Diseases





CTTI Recommendations: Decentralized Clinical Trials

September 2018



What do patients want?

Theme 2 **Empowered patients** – access to data, more control

While digitally supported healthcare professionals will play an important role in changing the way that healthcare is delivered, understanding how technology can have a positive impact on the patient experience is just as significant.

The general population is looking for information and more control over almost all aspects of their lives. Giving an individual access to their own health data makes them more likely to engage with it in a way that will improve the quality of care they receive and their overall healthcare experience.



What do patients want?



Diagnose Yourself, Anywhere

HEALTH

At rHEALTH®, we develop technologies that fundamentally change how people access analytical and diagnostic information*.

Combining portable diagnostic and monitoring capabilities will enable delivery of better and more timely health information. From this, we can begin to shift away from existing standards of curative medicine to future predictive, preemptive, and personalized medicine.

*rHEALTH devices are limited by FDA regulation for research or investigational purposes only.

What do patients prefer?



imaware[™] provides awareness of lifealtering diseases to empower patients to engage in personalized healthcare



Patient

aolo Barbant

imaware

New Players in healthcare

Amazon has explored getting into consumer health diagnostics — testing for disease at home

PUBLISHED FRI, DEC 14 2018 • 3:54 PM EST | UPDATED FRI, DEC 14 2018 • 4:10 PM EST



KEY

Amazon looked at buying a start-up developing at-home health tests called Confer POINTS Health, but talks broke down a few months ago.

> As recently as this summer, it had a team dedicated to diagnostics within its moonshots group "Grand Challenge." It is unknown whether the group is still active.

SHARE

 A move into the home health-testing space would be a signal of Amazon's ambitions to remake the entire health care supply chain, and could compete with testing giants Quest and LabCorp.



Patient

New Players in healthcare


Amazon, Google, Apple To Revolutionize Consumer Health Tech

August 20, 2019

The Healthcare Technology Report



With the proliferation of hardv homes and hands, it's only a r devices turn into sensors that practitioners to continuously n a very long time, the U.S. as a those in the healthcare field, h



rising cost of healthcare...

Digital Health







Digital Health Technologies

Digital Medicine

DIGITAL HEALTH

DIGITAL MEDICINE

measure

intervention

Digital Health Technologies


based on



EVIDENCE

Digital Medicine Technologies

Digital Medicine



Digital Health Tools

- measurement
- intervention

to optimize

- healthcare processes
- health outcomes

based on

scientific evidence



Applying digital technologies in drug discovery and clinical development






Digital Therapy

DIGITAL HEALTH

DIGITAL MEDICINE

Digital Health Technologies

based on



EVIDENCE

DIGITAL THERAPEUTICS

Digital Therapy Technologies

What are Digital Therapeutics?

Marketed

- a. Deprexis (EU 2009)
- b. Reset (FDA 2017)
- c. Reset-O (FDA 2017)
- d. Zemy (EU 2017)
- e. Oleena (FDA 2019)

Late Development

- a. AKL-T01 (FDA expected 2019)
- b. Somryst (FDA expected 2020?)
- c. CureApp Smoking Cessation (2020?)

Early Development

- a. MDD daVinci Digital Therapeutics
- b. Obesity daVinci Digital


Therapeutics

What are Digital Therapeutics?


- therapeutic interventions
- Active Ingredient is an Algorythm
- developed through RCTs
- approved by regulatory bodie
- subject to HTA assessment
- reimbursed by NHS / insur
- prescribed by a Physician

01],min:1,max:10 :"red1"}, {display_value:"green color:"olive", value:"olive"}, {display value:"tan"}]};\$(document).ready .on("click",".filter-option-log", type: "checkbox", display_title: ">nn-1xd", name color").ub_filter({type:"color", display ".filter-size").ub filter({type:"checkbox",disp. filter-shop").ub_filter({type:"checkbox", disp. uop)),\$(".filter-material").ub_filter({typ ter_data.material}), \$(".filter-price") _data.price}) }), function (a) {a.fn.ub pricerange min: "Cena od: ", filter type: 11, display title: "", name: d:getUniqueName("ub sel "hs-custom")

How is the Active Ingredient prepared?



Algorithms must take the «form» of



How do Digital Therapeutics work?

Combination with a

<u>drug</u>

- Monitoring of adherence to therapy
- Drug Dosage Recommendations
- Recommendations on AE
 management
- Diabetes (Voluntis w Roche, Sanofi)
- Oncology (Voluntis w AZ, Roche)
- Asthma / COPD (Propeller w GSK, Novartis, Chiesi; Teva; Adherium w AZ)

Standalone

- Cognitive Behavioural
 - **Therapies CBTs**
- Other therapeutic options
- Dependencies (Pear Therapeutics)
- Depression (daVinci Digital

Therapeutics)

- ADHD (Akili Interactive)
- Schizophrenia (Pear Therapeutics)
- Obesity (daVinci Digital Therapeutics)



New digital therapies



The future of substance use disorder treatment is **now available**

The first and only FDA-authorized prescription digital therapeutic to help treat substance use disorder '



reSET START YOUR THERAPY Repart your


Paolo Barbant Management Consulting Pharma & Biotech

Bringing the trial to the patient

Fundamentally shift the center of research from the hospital to the patient's home

Traditional Site Based Approach

Science 37 Patient-Centric Metasite[™] Model





New tools to monitor clinical trials







Resource Planner

Bringing rigor and discipline into FTE management



Leverage data insights to eliminate resourcing waste and improve productivity

of resources

portfolio and

line functions


across the

Holistic view of Resource **Management data** to drive the right conversations

 Provide the full picture of how resources are planned, benched, deployed and consumed across the trial lifecycle Enable deep learning and data driven allocation

Paolo Barbanti

Technology is rapidly evolving, providing opportunities to reimagine Drug Development



Key trends in healthcare

